BLADDER
A Phase II Trial of Pembrolizumab (MK-3475) in Subjets with Advanced / Unresectable or Metastatic Urothelial Cancer
MRK 2814 | 15-500
View full trial information
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
BMT
Prospective Outcomes of Second-line Therapy in Acute Graft-versus-Host Study including ECP POSTAGE
VICC 1Z14 | 14-1484
View full trial information
BRAIN
A Pilot Trial of Intraparenchymally-Administered Topotecan using Convection-Enhanced Delivery (CED) in Patients with Suspected Recurrent/Progressive WHO Grade III or IV (High Grade) Glioma Undergoing A Clinically-Indicated Surgical Resection (IND 117,240)
INFT 1315 | 15-614
View full trial information
BREAST
A study of Neratinib Plus Capecitabine versus Lapatinib Plus Capecitabine in patients with HER2+ Metastatic Breast Cancer who have received two or more prior HER2-directed regimens in the metastatic setting (NALA)
PUMA 1113 | CC031421C
View full trial information
LEUKEMIA, ACUTE MYELOID (AML)
A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
APGD 1914 | 14-863
View full trial information
LIVER
Multicenter Phase 1 b/2 Study of Tivozanib in Patients with Advanced Inoperable Hepatocellular Carcinoma
RPCI 1213 | 011419C
View full trial information
LUNG
CLVS 2514 (Tiger 1) Protocol entitled: A Randomized, Open-Label, Phase II Study of CO-1686 or Erlotinib First-Line Treatment of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)
CLVS 2514 | 15-019
View full trial information
LYMPHOMA
A Phase 2b Open-label, Randomized Two-arm Study Comparing High and Low Doses of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
KARY 1414 | 14-1340
View full trial information
MYELOMA
A phase 2, multicenter, single-arm, open-label study of pomalidomide in combination with low-dose dexamethasone in subjects with relapsed or refractory Multiple Myeloma following lenalidomide-based therapy in the second-line setting
CLGN 1A14 | 14-1374
View full trial information
PROSTATE
Phase III Trial for Enzalutamide versus Enzalutamide, Abiraterone and Prednisone for castration resistant metastatic prostate cancer
A031201| 14-332
View full trial information
SOLID TUMORS
A Phase 1, open-label study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of renal impairment
TAHO 1Y15 | 031501C
View full trial information
THROMBOCYTOPENIA, MYELOFIBROSIS
A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
CTI 1Z14 | 14-954
View full trial information
Search our Cancer Clinical Trials database for a full listing of all open and accruing studies: clevelandclinic.org/CancerClinicalTrials.
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access
Key learnings from DESTINY trials
Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors
Study of 401,576 patients reveals differences in cancer burdens as well as overall survival
Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy
